Peter A. Lio, MD

Current strategies used to evaluate the performance of therapies used to treat atopic dermatitis and guide formulary decisions, and recommendations to help patients receive access to effective therapies.

Payer and clinician insight regarding access to effective therapies for atopic dermatitis and potential challenges adopting new therapies, including topical JAK inhibitors, into clinical practice.

An overview of limitations faced by payers and clinicians who play a role in the management of atopic dermatitis.

Drs Shah and Lio explore where topical ruxolitinib fits into therapeutic sequencing in atopic dermatitis, compared with oral JAK inhibitors.

Dr Lio discusses features that make JAK inhibitors, including ruxolitinib, abrocitinib, baricitinib, and upadacitinib, attractive in the management of atopic dermatitis.

An overview of topical and oral therapies used to treat mild-to-moderate atopic dermatitis.

Considerations for quality measures established for atopic dermatitis when assessing how well patients are responding to treatment.

Indirect costs associated with atopic dermatitis, and the financial burden associated with delayed treatment initiation or inappropriate therapy.

The impact atopic dermatitis and associated comorbidities have on patients with the condition, as well as family members.

An overview of what has been learned over time that can help dermatologists and other community physicians appropriately identify signs of atopic dermatitis in children and adults.